Protagenic Therapeutics (PTIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protagenic Therapeutics (PTIX) has a cash flow conversion efficiency ratio of 0.087x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-410.42K) by net assets ($-4.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Protagenic Therapeutics - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Protagenic Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Protagenic Therapeutics carry for a breakdown of total debt and financial obligations.
Protagenic Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protagenic Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shield Therapeutics plc
LSE:STX
|
0.303x |
|
Thiensurat Public Company Limited
BK:TSR
|
-0.011x |
|
Boxlight Corp Class A
NASDAQ:BOXL
|
0.143x |
|
Biophytis S.A.
PA:ALBPS
|
0.472x |
|
BEACN Wizardry & Magic Inc
V:BECN
|
-1.349x |
|
Total Helium Ltd
V:TOH
|
0.006x |
|
AfriTin Mining Ltd
LSE:ATM
|
-0.033x |
|
Edri-El
TA:EDRL
|
0.013x |
Annual Cash Flow Conversion Efficiency for Protagenic Therapeutics (1995–2025)
The table below shows the annual cash flow conversion efficiency of Protagenic Therapeutics from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see PTIX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-4.69 Million | $-4.14 Million | 0.882x | +121.20% |
| 2024-12-31 | $1.01 Million | $-4.22 Million | -4.162x | -312.17% |
| 2023-12-31 | $3.67 Million | $-3.70 Million | -1.010x | -250.32% |
| 2022-12-31 | $6.92 Million | $-1.99 Million | -0.288x | -2.39% |
| 2021-12-31 | $9.94 Million | $-2.80 Million | -0.281x | -124.00% |
| 2020-12-31 | $-1.15 Million | $-1.35 Million | 1.173x | +52.50% |
| 2019-12-31 | $-634.37K | $-487.99K | 0.769x | -84.86% |
| 2018-12-31 | $-210.88K | $-1.07 Million | 5.080x | +548.78% |
| 2017-12-31 | $1.22 Million | $-1.38 Million | -1.132x | -145.87% |
| 2016-12-31 | $2.48 Million | $-1.14 Million | -0.460x | -169.54% |
| 2015-12-31 | $-571.00K | $-378.00K | 0.662x | -12.96% |
| 2015-06-30 | $-497.00K | $-378.00K | 0.761x | -93.26% |
| 2014-12-31 | $-70.00K | $-790.00K | 11.286x | 0.00% |
| 2013-12-31 | $-70.00K | $-790.00K | 11.286x | +59902.38% |
| 2012-12-31 | $-17.23 Million | $-324.00K | 0.019x | +101.37% |
| 2010-12-31 | $8.17 Million | $-11.25 Million | -1.377x | -1057.35% |
| 2009-12-31 | $25.35 Million | $-3.02 Million | -0.119x | -249.26% |
| 2008-12-31 | $54.65 Million | $4.36 Million | 0.080x | +125.80% |
| 2007-12-31 | $16.86 Million | $-5.21 Million | -0.309x | -140.58% |
| 2006-12-31 | $1.22 Million | $931.00K | 0.761x | +347.54% |
| 2004-12-31 | $2.74 Million | $-842.00K | -0.308x | -181.90% |
| 2003-12-31 | $4.98 Million | $1.87 Million | 0.376x | +106.06% |
| 2002-12-31 | $12.87 Million | $2.35 Million | 0.182x | +64.37% |
| 2001-12-31 | $13.57 Million | $1.50 Million | 0.111x | -56.20% |
| 2000-12-31 | $13.86 Million | $3.51 Million | 0.253x | +915.01% |
| 1999-12-31 | $13.27 Million | $331.00K | 0.025x | +180.14% |
| 1998-12-31 | $13.95 Million | $-434.00K | -0.031x | +81.20% |
| 1997-12-31 | $13.30 Million | $-2.20 Million | -0.166x | -406.58% |
| 1996-12-31 | $7.04 Million | $-230.00K | -0.033x | +59.11% |
| 1995-12-31 | $7.51 Million | $-600.00K | -0.080x | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.